SEC Form SC 13G/A filed by Pacira BioSciences Inc. (Amendment)

2/10/22 5:22:10 PM ET

Biotechnology: Pharmaceutical Preparations

Health Care

Get the next $PCRX alert in real time by email

SC 13G/A 1 pcrx-13g_20211231.txt UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* PACIRA BIOSCIENCES, INC. ---------------------------------------------------------------------------- (Name of Issuer) Common Stock, par value $0.001 per share ---------------------------------------------------------------------------- (Title of Class of Securities) 695127100 ---------------------------------------------------------------------------- (CUSIP Number) December 31, 2021 ---------------------------------------------------------------------------- (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [X] Rule 13d-1(b) [_] Rule 13d-1(c) [_] Rule 13d-1(d) *The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page. The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes). ============================================================================= ----------------------------------------------------------------------------- CUSIP NO. 695127100 13G Page 2 of 8 Pages ----------------------------------------------------------------------------- (1) NAMES OF REPORTING PERSONS. I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (entities only). Renaissance Technologies LLC 26-0385758 ----------------------------------------------------------------------------- (2) CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS): (a) [_] (b) [_] ----------------------------------------------------------------------------- (3) SEC USE ONLY ----------------------------------------------------------------------------- (4) CITIZENSHIP OR PLACE OF ORGANIZATION Delaware ----------------------------------------------------------------------------- (5) SOLE VOTING POWER NUMBER OF SHARES 1,849,197 BENEFICIALLY OWNED _____________________________ BY EACH REPORTING PERSON WITH: (6) SHARED VOTING POWER 0 _____________________________ (7) SOLE DISPOSITIVE POWER 1,849,197 _____________________________ (8) SHARED DISPOSITIVE POWER 0 ______________________________ (9) AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 1,849,197 ------------------------------------------------------------------------------ (10) CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS) [_] ------------------------------------------------------------------------------ (11) PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9) 4.15 % ------------------------------------------------------------------------------ (12) TYPE OF REPORTING PERSON (SEE INSTRUCTIONS) IA Page 2 of 8 pages ============================================================================= Page 3 of 8 pages ----------------------------------------------------------------------------- CUSIP NO. 695127100 13G Page 3 of 8 Pages ----------------------------------------------------------------------------- (1) NAMES OF REPORTING PERSONS. I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY). RENAISSANCE TECHNOLOGIES HOLDINGS CORPORATION 13-3127734 ----------------------------------------------------------------------------- (2) CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS) (a) [_] (b) [_] ----------------------------------------------------------------------------- (3) SEC USE ONLY ----------------------------------------------------------------------------- (4) CITIZENSHIP OR PLACE OF ORGANIZATION Delaware ----------------------------------------------------------------------------- (5) SOLE VOTING POWER NUMBER OF SHARES 1,849,197 BENEFICIALLY OWNED _____________________________ BY EACH REPORTING PERSON WITH: (6) SHARED VOTING POWER 0 _____________________________ (7) SOLE DISPOSITIVE POWER 1,849,197 _____________________________ (8) SHARED DISPOSITIVE POWER 0 _____________________________ (9) AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 1,849,197 ----------------------------------------------------------------------------- (10) CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS) [_] ----------------------------------------------------------------------------- (11) PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9) 4.15 % ----------------------------------------------------------------------------- (12) TYPE OF REPORTING PERSON (SEE INSTRUCTIONS) HC Page 3 of 8 pages ============================================================================= ----------------------------------------------------------------------------- CUSIP NO. 695127100 13G Page 4 of 8 Pages ----------------------------------------------------------------------------- Item 1. (a) Name of Issuer PACIRA BIOSCIENCES, INC. (b) Address of Issuer's Principal Executive Offices. 5401 West Kennedy Boulevard, Suite 890, Tampa, Florida, 33609 Item 2. (a) Name of Person Filing: This Schedule 13G is being filed by Renaissance Technologies LLC ("RTC") and Renaissance Technologies Holdings Corporation ("RTHC"). (b) Address of Principal Business Office or, if none, Residence. The principal business address of the reporting persons is: 800 Third Avenue New York, New York 10022 (c) Citizenship. RTC is a Delaware limited liability company, and RTHC is a Delaware corporation. (d) Title of Class of Securities. Common Stock, par value $0.001 per share (e) CUSIP Number. 695127100 Page 4 of 8 pages ============================================================================= Item 3. If this statement is filed pursuant to Rule 13d-1(b) or 13-d-2(b) or (c),check whether the person filing is a: (a) [_] Broker or dealer registered under section 15 of the Act. (b) [_] Bank as defined in section 3(a)(6) of the Act. (c) [_] Insurance Company as defined in section 3(a)(19) of the Act. (d) [_] Investment Company registered under section 8 of the Investment Company Act. (e) [x] Investment Adviser in accordance with Sec.240.13d-1(b)(1)(ii)(E). (f) [_] Employee Benefit Plan or Endowment Fund in accordance with Sec. 240.13d-1(b)(1)(ii)(F). (g) [_] Parent holding company, in accordance with Sec.240.13d-1(b)(1)(ii)(G). (h) [_] A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act. (i) [_] A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940. (j) [_] Group, in accordance with Sec.240.13d-1(b)(1)(ii)(J). Item 4. Ownership. (a) Amount beneficially owned. RTC: 1,849,197 shares RTHC: 1,849,197 shares, comprising the shares beneficially owned by RTHC, because of RTHC's majority ownership of RTC. (b) Percent of Class. RTC: 4.15 % RTHC: 4.15 % (c) Number of shares as to which the person has: (i) sole power to vote or to direct the vote: RTC: 1,849,197 RTHC: 1,849,197 (ii) Shared power to vote or to direct the vote: 0 (iii) sole power to dispose or to direct the disposition of: RTC: 1,849,197 RTHC: 1,849,197 (iv) Shared power to dispose or to direct the disposition of: RTC: 0 RTHC: 0 Page 5 of 8 pages ============================================================================= Item 5. Ownership of Five Percent or Less of a Class. If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following: [X] Item 6. Ownership of More than Five Percent on Behalf of Another Person. Certain funds and accounts managed by RTC have the right to receive dividends and proceeds from the sale of the securities which are the subject of this report. Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company. Not applicable Item 8. Identification and Classification of Members of the Group. Not applicable Item 9. Notice of Dissolution of a Group. Not applicable Page 6 of 8 pages ============================================================================= Item 10. Certification By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect. SIGNATURE After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct. Date: February 10, 2022 Renaissance Technologies LLC By: /s/ James S. Rowen Chief Operating Officer Renaissance Technologies Holdings Corporation By: /s/ James S. Rowen Vice President Attention: Intentional misstatements or omissions of fact constitute Federal criminal violations (See 18 U.S.C. 1001). Page 7 of 8 Pages ============================================================================== EXHIBIT 99.1 AGREEMENT REGARDING JOINT FILING UNDER RULE 13D-1(K) OF THE EXCHANGE ACT In accordance with Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended, each of the undersigned agrees to the filing on behalf of each of a Statement on Schedule 13G, and all amendments thereto, with respect to the shares of Common Stock, par value $0.001 per share of PACIRA BIOSCIENCES, INC. Date: February 10, 2022 Renaissance Technologies LLC By: /s/ James S. Rowen Chief Operating Officer Renaissance Technologies Holdings Corporation By: /s/ James S. Rowen Vice President Page 8 of 8 Pages

Get the next $PCRX alert in real time by email

Recent Analyst Ratings for

$PCRX

Date	Price Target	Rating	Analyst
12/9/2025	$27.00	Equal Weight	Barclays
11/17/2025		Buy	H.C. Wainwright
7/25/2025	$30.00	Hold → Buy	Truist
1/30/2025	$8.00 → $25.00	Sell → Hold	Truist
8/13/2024	$30.00 → $8.00	Buy → Sell	Truist
8/12/2024	$42.00 → $11.00	Overweight → Neutral	Piper Sandler
8/12/2024	$45.00 → $10.00	Overweight → Underweight	JP Morgan
8/12/2024		Outperform → Mkt Perform	Raymond James

More analyst ratings

SEC Form SC 13G/A filed by Pacira BioSciences Inc. (Amendment)

2/10/22 5:22:10 PM ET

$PCRX

Biotechnology: Pharmaceutical Preparations

Health Care

Get the next $PCRX alert in real time by email

Recent Analyst Ratings for

$PCRX

Date	Price Target	Rating	Analyst
12/9/2025	$27.00	Equal Weight	Barclays
11/17/2025		Buy	H.C. Wainwright
7/25/2025	$30.00	Hold → Buy	Truist
1/30/2025	$8.00 → $25.00	Sell → Hold	Truist
8/13/2024	$30.00 → $8.00	Buy → Sell	Truist
8/12/2024	$42.00 → $11.00	Overweight → Neutral	Piper Sandler
8/12/2024	$45.00 → $10.00	Overweight → Underweight	JP Morgan
8/12/2024		Outperform → Mkt Perform	Raymond James

More analyst ratings

SEC Form SC 13G/A filed by Pacira BioSciences Inc. (Amendment)

Crush Q1 2026 with the Best AI Superconnector

Recent Analyst Ratings for
$PCRX

SEC Form SC 13G/A filed by Pacira BioSciences Inc. (Amendment)

Crush Q1 2026 with the Best AI Superconnector

Recent Analyst Ratings for
$PCRX

$PCRX
SEC Filings

SEC Form DEFA14A filed by Pacira BioSciences Inc.

SEC Form DEFA14A filed by Pacira BioSciences Inc.

SEC Form DEFA14A filed by Pacira BioSciences Inc.

$PCRX
Press Releases

Pacira BioSciences Highlights Leading Independent Proxy Advisory Firm ISS' Recommendation to Vote "FOR" All of Pacira's Director Nominees

Leading Independent Proxy Advisory Firm Glass Lewis Recommends Stockholders Vote "FOR" All of Pacira's Director Nominees

DOMA PERPETUAL CAPITAL MANAGEMENT QUESTIONS WHY SHAREHOLDERS SHOULD VOTE TO CONTINUE WITH A BOARD THAT HAS OVERSEEN A DECADE OF VALUE DESTRUCTION

$PCRX
Analyst Ratings

Barclays initiated coverage on Pacira BioSciences with a new price target

H.C. Wainwright initiated coverage on Pacira BioSciences

Pacira BioSciences upgraded by Truist with a new price target

$PCRX
Insider Purchases

Director Bigal Marcelo bought $20,034 worth of shares (1,512 units at $13.25), increasing direct ownership by 18% to 10,142 units (SEC Form 4)

Director Brege Laura bought $12,810 worth of shares (1,000 units at $12.81), increasing direct ownership by 6% to 17,552 units (SEC Form 4)

Director Yang Michael J. bought $25,800 worth of shares (2,000 units at $12.90), increasing direct ownership by 38% to 7,230 units (SEC Form 4)

$PCRX
Insider Trading

Chief Financial Officer Cross Shawn exercised 12,941 shares at a strike of $16.45 and sold $325,596 worth of shares (12,941 units at $25.16) as part of a pre-agreed trading plan (SEC Form 4)

SEC Form 4 filed by Cross Shawn

Amendment: SEC Form 4 filed by Kronenfeld Mark A.

$PCRX
Leadership Updates

Pacira BioSciences Mails Letter to Stockholders Reiterating Confidence in the Company's Strategic Direction and Highly Qualified Nominees

After Fifty Years of Implants, a Newly Public Biotech Is Trying to Rebuild the Breast Instead

Pacira BioSciences Appoints Samit Hirawat, M.D., to Board of Directors

$PCRX
Financials

Pacira BioSciences Reports First Quarter 2026 Financial Results

Pacira to Report First Quarter 2026 Financial Results on Thursday April 30, 2026

Pacira BioSciences Reports Fourth Quarter and Full-Year 2025 Financial Results

$PCRX
Large Ownership Changes